We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+0.45%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$520M
AUM Growth
+$3.52M
(+0.68%)
Cap. Flow
+$20.7M
Cap. Flow
% of AUM
3.98%
Top 10 Holdings %
Top 10 Hldgs %
23.77%
Holding
129
New
9
Increased
50
Reduced
34
Closed
11
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mineralys Therapeutics
MLYS
|
+$10.3M |
| 2 |
TSVT
2seventy bio
TSVT
|
+$5.44M |
| 3 |
Vera Therapeutics
VERA
|
+$4.63M |
| 4 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
+$4.57M |
| 5 |
Treace Medical Concepts
TMCI
|
+$4.38M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$8.88M |
| 2 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$5.52M |
| 3 |
iRhythm Holdings
IRTC
|
+$4.01M |
| 4 |
Arrowhead Research
ARWR
|
+$3.87M |
| 5 |
HealthEquity
HQY
|
+$3.67M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 95.06% |
| 2 | Industrials | 4.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Incyte
INCY
$24.4B
| $483K | 0.09% |
6,680
| – | – |
|
102
Legend Biotech
LEGN
$3.7B
| $482K | 0.09% |
10,000
+1,000
| +11% | +$48.9K |
|
103
Dr. Reddy's Laboratories
RDY
$10.1B
| $456K | 0.09% |
40,020
-10,000
| -20% | -$108K |
|
104
Royalty Pharma
RPRX
$25.5B
| $448K | 0.09% |
12,440
| – | – |
|
105
United Therapeutics
UTHR
$22B
| $406K | 0.08% |
1,815
| – | – |
|
106
Zai Lab
ZLAB
$2.09B
| $397K | 0.08% |
11,922
-1,500
| -11% | -$57.6K |
|
107
BioNTech
BNTX
$23.1B
| $336K | 0.06% |
2,700
| – | – |
|
108
Jazz Pharmaceuticals
JAZZ
$16.4B
| $318K | 0.06% |
2,170
+200
| +10% | +$29.6K |
|
109
argenx
ARGX
$52.8B
| $317K | 0.06% |
850
-80
| -9% | -$29.6K |
|
110
Neurocrine Biosciences
NBIX
$16.9B
| $283K | 0.05% |
2,800
| – | – |
|
|
FUSN
111
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $216K | 0.04% |
57,297
| – | – |
|
112
Medpace
MEDP
$16.1B
| $182K | 0.04% |
970
| – | – |
|
113
Ascendis Pharma A/S
ASND
$16B
| $181K | 0.03% |
1,690
| – | – |
|
114
Roivant Sciences
ROIV
$25B
| $155K | 0.03% |
21,000
| – | – |
|
115
Madrigal Pharmaceuticals
MDGL
$11.7B
| $121K | 0.02% |
+500
| New | +$136K |
|
116
NovoCure
NVCR
$1.89B
| $105K | 0.02% |
1,750
+150
| +9% | +$12K |
|
117
Intellia Therapeutics
NTLA
$1.58B
| $92.4K | 0.02% |
2,480
-68,900
| -97% | -$2.7M |
|
118
Summit Therapeutics
SMMT
$11B
| $35K | 0.01% |
+20,000
| New | +$54.5K |
|
|
119
Arrowhead Research
ARWR
$12.6B
| – | – |
-95,400
| Closed | -$3.87M |
|
120
BioXcel Therapeutics
BTAI
$26.6M
| – | – |
-3,822
| Closed | -$1.31M |
|
121
CRISPR Therapeutics
CRSP
$5.23B
| – | – |
-2,490
| Closed | -$101K |
|
|
122
Exelixis
EXEL
$14.1B
| – | – |
-553,475
| Closed | -$8.88M |
|
123
Fate Therapeutics
FATE
$300M
| – | – |
-183,000
| Closed | -$1.85M |
|
124
Guardant Health
GH
$21.4B
| – | – |
-4,770
| Closed | -$130K |
|
125
Ionis Pharmaceuticals
IONS
$9.15B
| – | – |
-4,450
| Closed | -$168K |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, Sectoral Asset Management held 129 positions worth $520M, up 0.68% from $517M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Sectoral Asset Management deployed $20.7M of net new capital in Q1 2023, opening 9 new positions and adding to 50 existing holdings. Its largest new stake was Mineralys Therapeutics: 613,233 shares worth $9.6M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was R1 RCM Inc. Common Stock, an estimated $5.52M trimmed.
- Sectoral Asset Management's largest Q1 2023 buy was Mineralys Therapeutics: 613,233 shares worth $9.6M.
- Sectoral Asset Management added most to Shockwave Medical, Inc. Common Stock in Q1 2023, an estimated $4.57M increase.
- Sectoral Asset Management's biggest Q1 2023 reduction was R1 RCM Inc. Common Stock, cutting an estimated $5.52M.
- Sectoral Asset Management fully exited Exelixis in Q1 2023, selling an estimated $8.88M.
- Sectoral Asset Management's ten largest holdings make up 24% of its $520M portfolio in Q1 2023.
- Sectoral Asset Management opened 9 new positions and closed 11 in Q1 2023.
- Sectoral Asset Management's portfolio value rose 0.68% quarter-over-quarter to $520M.
Based on Sectoral Asset Management's 13F filing for Q1 2023, filed 12 May 2023.